{
    "organizations": [],
    "uuid": "e5af0f67be019ea8ed1ecee6124ed3e4388224c2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-idt-australia-to-divest-selection/brief-idt-australia-to-divest-selection-of-generic-product-portfolio-to-ani-pharmaceuticals-idUSFWN1RG0UB",
    "ord_in_thread": 0,
    "title": "BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - IDT Australia Ltd:\n* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC\n* ‍IDT WILL RECEIVE US$2.7 MILLION * ‍IDT WILL RETAIN A SHARE OF NET PROFIT FROM PRAZOSIN FUTURE SALES FOR 60 MONTHS​\n* WILL RETAIN RIGHT TO MANUFACTURE AND SUPPLY DOXAZOSIN MESYLATE AND CALCIUM LEUCOVORIN ON A CONTRACT MANUFACTURE FOR PROFIT BASIS​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-04T07:30:00.000+03:00",
    "crawled": "2018-04-04T12:33:20.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "idt",
        "australia",
        "ltd",
        "divest",
        "selection",
        "generic",
        "product",
        "portfolio",
        "ani",
        "pharmaceutical",
        "inc",
        "receive",
        "u",
        "million",
        "retain",
        "share",
        "net",
        "profit",
        "prazosin",
        "future",
        "sale",
        "retain",
        "right",
        "manufacture",
        "supply",
        "doxazosin",
        "mesylate",
        "calcium",
        "leucovorin",
        "contract",
        "manufacture",
        "profit",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}